Induced neural stem cells could promote stroke recovery, prevent damage

Neuron 2

New research out of Japan has demonstrated that induced neural stem cells can help patients recover after a stroke and possibly, when administered early, prevent some of the most severe damage altogether.

Induced neural stem cells, or iNSCs, are somatic cells that have been directly differentiated into neural stem cells, as opposed to pluripotent stem cells, which can differentiate into a number of final products. Scientists from Okayama University found that these iNSCs might be more tolerable in vivo than pluripotents because they derive from the somatic cells without extra steps in between.

In mice with ischemic stroke, the iNSCs exerted a therapeutic effect and promoted functional recovery. What’s more, the cells also protected the brain from ischemia-related damage when administered during the early stages of a stroke.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

The researchers published their findings in the journal Cell Transplantation.

“We observed multiple therapeutic effects when using these cells to treat stroke in mice,” Okayama’s Dr. Koji Abe said in a statement. “The iNSCs did not produce any adverse responses in the animals, including tumor formation, which may suggest they are safer than regular iPSCs. Further studies are needed to confirm this cell type as a candidate for cell replacement therapy for stroke.”


Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.